Litcius/Paper detail

Thermostability of Measles and Rubella Vaccines in a Microneedle Patch

Jessica C. Joyce, Marcus L. Collins, Paul A. Rota, Mark R. Prausnitz

2021Advanced Therapeutics22 citationsDOIOpen Access PDF

Abstract

Abstract Measles and rubella vaccinations are highly effective at reducing disease prevalence; however, logistic issues related to subcutaneous administration and vaccine wastage limit the extent of vaccination coverage. Microneedle (MN) patches can increase coverage by easing logistics through simplified administration and improved stability. This study demonstrates the thermostability of a bivalent measles and rubella vaccine MN patch. The data show that rubella vaccine stability requires pH buffering during drying; potassium phosphate buffer at neutral pH is optimal for both vaccines. Screening 43 excipients for their ability to retain potency during drying and storage yields sucrose‐threonine‐potassium phosphate buffer formulation at pH 7.5 as an optimal formulation. MN patches made with this formulation have no significant loss of vaccine titer after 1 month and remain within a one log 10 titer loss cutoff after 3–4 months at 5, 25, and 40 °C. Finally, these patches are shown to be immunogenic in juvenile rhesus macaques. This work demonstrates the potential for MN patches for measles and rubella vaccination to be removed from the cold chain, which is expected to decrease vaccine cost and wastage, and increase vaccination coverage.

Topics & Concepts

RubellaMeaslesVaccinationRubella vaccineMeasles vaccineTiterThermostabilityPhosphate buffered salineMedicineVirologyChemistryImmunologyVirusChromatographyBiochemistryEnzymeAdvancements in Transdermal Drug DeliveryTransgenic Plants and ApplicationsAdvanced Drug Delivery Systems
Thermostability of Measles and Rubella Vaccines in a Microneedle Patch | Litcius